LHDX - COVID-19 test maker Cue Health prices 12.5M-share IPO at $16

Cue Health (NASDAQ:HLTH) has priced its IPO of 12.5M shares of common stock at $16.00/share, for gross proceeds of $200M at a target valuation of around $2.4B. Nasdaq trading commences on September 24, 2021. Underwriters' over-allotment is an additional 1.875M shares. Closing date is September 28. Founded in 2010, San Diego-based Cue Health is a health technology company offering lab-quality diagnostic testing at home, at work, or at the point-of-care. Cue's COVID-19 Test Kit with Cue Health Monitoring System has two FDA Emergency Use Authorizations, for point-of-care and over-the-counter and at-home use. The company's expected future care offerings also include tests and other products across multiple categories, including respiratory health, sexual health, cardiac and metabolic health, women's health, men's health, and chronic disease management. HLTH expects to begin submitting additional tests for FDA authorization or clearance in H2 2022. Other companies offering COVID testing or related servics are Lucira Health (NASDAQ:LHDX), Biodesix (NASDAQ:BDSX),

For further details see:

COVID-19 test maker Cue Health prices 12.5M-share IPO at $16